8-K: Rani Therapeutics Reports Q2 2026 Results, Advances RT-114

Rani Therapeutics announced second quarter 2026 financial results, highlighting positive initial Phase 1a data for RT-114, a $20 million capital raise, and a new collaboration with PegBio.

Summary

• Rani Therapeutics reported its financial results for the second quarter ended June 30, 2026.
• The company announced positive initial Phase 1a data for its RT-114 drug candidate, showing oral bioavailability over 150% compared to subcutaneous dosing.
• First participants were dosed in the Phase 1a expansion cohort for RT-114, with additional data expected by the end of 2026.
• A new research and development collaboration with PegBio was established to explore oral delivery of obesity and metabolic disease molecules using the RaniPill platform.
• Rani Therapeutics completed a $20 million registered direct offering in May 2026.
• Nicholas Maestas was appointed as Chief Financial Officer in June 2026, and Michelle Gilson joined the Board of Directors in August 2026.
• Cash, cash equivalents, and marketable securities totaled $53.4 million as of June 30, 2026, expected to fund operations through 2027.
• Net loss for the quarter was $8.4 million, an improvement from $11.2 million in the prior year's quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by promising clinical data and strategic collaborations, despite ongoing net losses.

Positives

• Positive initial Phase 1a data for RT-114, demonstrating oral bioavailability greater than 150% relative to matched subcutaneous dosing.
• Advancement of RT-114 into the Phase 1a expansion cohort, with additional data anticipated by year-end 2026.
• New R&D collaboration with PegBio to expand the obesity pipeline using the RaniPill platform.
• Successful completion of a $20 million registered direct offering, strengthening the company's cash position.
• Appointment of experienced financial leader Nicholas Maestas as CFO.
• Addition of Michelle Gilson to the Board of Directors, bringing valuable expertise.
• Contract revenue of $1.7 million for the quarter, primarily from the Chugai collaboration, compared to no revenue in the prior year.
• Reduced net loss to $8.4 million for the quarter, down from $11.2 million in Q2 2025.

Negatives

• Continued net loss of $8.4 million for the three months ended June 30, 2026.
• Research and development expenses were $5.0 million for the quarter, while general and administrative expenses were $5.5 million.
• Accumulated deficit stands at $147.0 million as of June 30, 2026.

Risks

• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• Risks associated with Rani's business in general, as described in its SEC filings.
• Potential for delays in clinical development timelines or unexpected trial outcomes.
• Challenges in successfully developing and commercializing oral biologic therapies.
• Reliance on collaborations with third parties, such as PegBio and ProGen.

Future Outlook

The company expects its cash, cash equivalents, and marketable securities to be sufficient to fund its operations at least through 2027. Additional data from the RT-114 Phase 1a expansion cohort is expected by the end of 2026, with a Phase 1b study in patients with obesity anticipated to initiate by the end of 2026 and data in 2027. The collaboration with PegBio aims to advance promising candidates into clinical development.

Management Comments

• "We made significant progress in the second quarter, as we continue to expand the RaniPill oral delivery platform."
• "We reported positive initial Phase 1a data for RT-114 showing oral bioavailability that exceeded matched subcutaneous dosing. These data are consistent with the bioavailability that we have seen in previous preclinical and clinical studies with the RaniPill."
• "We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026."
• "We also continued to expand our obesity franchise through a new collaboration with PegBio leveraging the RaniPill platform to explore the oral delivery of novel obesity and metabolic disease molecules across multiple mechanisms of action."
• "I am also pleased to have welcomed Nicholas Maestas as our Chief Financial Officer and Michelle Gilson to our Board of Directors."
• "Together, these clinical and corporate milestones, along with the completion of a $20 million registered direct offering, position Rani to make further progress in the development of the RaniPill as an oral delivery for biologic candidates."

Industry Context

StockSavvy.ai notes that Rani Therapeutics is operating in the highly competitive and innovative biotherapeutics sector, focusing on the challenging but potentially lucrative area of oral delivery for biologics. The company's progress with RT-114 and its collaboration with PegBio align with broader industry trends towards developing more convenient and patient-friendly drug administration methods, particularly for chronic conditions like obesity.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if clinical milestones are met and the RaniPill platform proves successful; dilution from the recent capital raise.
• Employees: Continued employment and potential for growth as the company advances its pipeline.
• Partners (e.g., Chugai, PegBio, ProGen): Continued collaboration and potential for shared success in developing new therapies.

Next Steps

• Advance RT-114 in the clinic with additional data from the Phase 1a expansion cohort expected by the end of 2026.
• Initiate a Phase 1b repeat-dose study in patients with obesity by the end of 2026, with data anticipated in 2027.
• Collaborate with PegBio on the preclinical development of RaniPill formulations for multiple obesity and metabolic disease molecules.
• Advance promising candidates from the PegBio collaboration into clinical development.

Key Dates

Recommendation

The company has demonstrated promising early-stage clinical data for RT-114 and secured necessary funding, positioning it for continued development. However, the significant net losses and the early stage of development warrant a cautious 'hold' rating until further clinical validation and progress towards commercialization are evident.

Keywords

RaniPill, RT-114, oral biologics, Phase 1a, obesity, metabolic disease, pharmacokinetics, GLP-1/GLP-2